We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer.
- Authors
Bensinger, W I; Schiffman, K S; Holmberg, L; Appelbaum, F R; Maziarz, R; Montgomery, P; Ellis, E; Rivkin, S; Weiden, P; Lilleby, K; Rowley, S; Petersdorf, S; Klarnet, J P; Nichols, W; Hertler, A; McCroskey, R; Weaver, C H; Buckner, C D
- Abstract
The purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) infusion. Fifty-one patients with chemotherapy refractory (n= 32) or responsive (n= 19) metastatic breast cancer received Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) followed by PBSC collected after chemotherapy and growth factor (n= 43) or growth factor alone (n = 8). The 100 day treatment-related mortality was 8% including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two from regimen-related toxicity (RRT). Seven of 28 refractory (25%) and 5/7 (71%) responsive patients with evaluable disease achieved a complete response of all measurable disease or all soft tissue disease with at least improvement in bone lesions (PR*). Fifteen of 51 patients (29%) are alive and progression-free a median of 423 days (range 353–934) after treatment, 5/32 (16%) with refractory disease and 10/19 (53%) with responsive disease. The probabilities of progression-free survival (PFS) at 1.5 years for the patients with refractory (n= 32) and responsive (n = 19) disease were 0.24 and 0.53, respectively. These preliminary data suggest that high-dose Bu/Mel/TT has significant activity in patients with advanced breast cancer and may be superior to some previously published regimens.
- Subjects
BREAST cancer; THERAPEUTICS; ANTINEOPLASTIC agents
- Publication
Bone Marrow Transplantation, 1997, Vol 19, Issue 12, p1183
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/sj.bmt.1700820